| Oct 21 |
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
|
| Oct 7 |
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
|
| Sep 24 |
Revolution Medicines added to JPMorgan focus list due to NSCLC asset
|
| Sep 14 |
Revolution Medicines, Inc. (RVMD): Among Hedge Funds’ Top Biotech Stock Picks
|
| Sep 9 |
Revolution Medicines: It's Full Steam Ahead, But I Wouldn't Buy At These Levels
|
| Aug 11 |
Revolution Medicines, Inc. 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 11 |
Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript
|
| Aug 9 |
Revolution Medicines First Half 2024 Earnings: US$1.51 loss per share (vs US$1.64 loss in 1H 2023)
|
| Aug 8 |
Q2 2024 Revolution Medicines Inc Earnings Call
|
| Aug 7 |
Revolution Medicines GAAP EPS of -$0.81 misses by $0.03
|
